Dr Emily Sammons
Contact information
Emily Sammons
BSc, MBChB, MSc
Clinical Research Fellow
Dr Emily Sammons is a Clinical Research Fellow and DPhil student at the Clinical Trial Service Unit & Epidemiological Studies Unit (CTSU), with particular research interests in diabetic eye disease and age-related macular degeneration.
Alongside this, she works on two large randomised controlled trials: ASCEND and REVEAL.
ASCEND is studying whether aspirin and omega-3 fish oil supplementation protects against cardiovascular disease in people with diabetes.
REVEAL is assessing the safety and benefits of taking a new lipid-modifying drug called anacetrapib, by those with pre-existing atherosclerotic vascular disease.
Emily has background experience of working in General Medicine and a MSc in Public Health.
Recent publications
Cost-effectiveness of fenofibrate versus standard care for reducing the progression of diabetic retinopathy: An economic evaluation based on data from the LENS trial.
Journal article
Scotland G. et al, (2025), Diabet Med, 42
Experience of linking to the NHS diabetic eye screening programme records in the ASCEND-eye randomized trial and recommendations for improvement.
Journal article
Sammons E. et al, (2025), Contemp Clin Trials Commun, 45
The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial.
Journal article
Judge PK. et al, (2025), Nephrol Dial Transplant, 40, 1175 - 1186
Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial.
Journal article
Mayne KJ. et al, (2025), Nephrol Dial Transplant, 40, 720 - 730
Effects of aspirin and omega-3 fatty acids on age-related macular degeneration in ASCEND-Eye: a randomised placebo-controlled trial in a population with diabetes.
Journal article
Sammons E. et al, (2025), BMJ Open, 15